

<b>FORM PTO-1449</b> Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. <b>AMI-011-RC2</b>		Serial No. <b>10/015,534</b>	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicant <b>Burton G. Christensen et al.</b>		Filing Date <b>December 13, 2001</b>	
				Group Art Unit <b>1627</b>			

MAY 22 2002  
 10:55 33  
 PATENT & TRADEMARK OFFICE


U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	A1	<del>*4,587,046</del>		Goodman et al.			
	previously A2	<del>*5,463,564</del>		Agrafiotis et al.			
	considered A3	<del>*5,607,921</del>		Bernard et al.			
	A4	<del>5,891,643</del>		Fesik et al.			
	A5	<del>*5,962,701</del>		Rosenau et al.			


FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	<del>*97/00244</del>		WIPO				
	B2	<del>*98/02186</del>		WIPO				
	previously B3	<del>98/16536</del>		WIPO				
	considered B4	<del>98/16638</del>		WIPO				
	B5	<del>*0306904</del>		EPO				
	B6	<del>*0433043</del>		EPO				
→	mg	B7	0825191	EPO				
→	previously considered	B8	2317173	GB				
→	mg	B9	62-164609	JP				considered only to extent of translated abstract


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
C1	*Adham et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 348:556-575 (1993)
C2	*Adham et al., Neuropharmacol. 36(4/5):569-576 (1997)
previously C3	*Alabaster, Life Sci. 60(13/14):1053-1060 (1997)
C4	*Bartow et al., Drugs 55(2):303-322 (1998)
considered C5	*Beer et al., Br. J. Pharmacol. 110:1196-1200 (1993)
C6	*Bergendal et al., Br. J. Pharmacol. 117:1009-1015 (1996)
C7	*Bergsma et al., Biochem. Biophys. Res. Comm. 183:989-995 (1992)
C8	*Boulet, Drugs 47(2):207-222 (1994)

EXAMINER <i>mm</i>	DATE CONSIDERED <b>6/3/2005</b>
--------------------	---------------------------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to applicant.

<b>FORM PTO 1449</b> Approved for use through 10/31/2002 <b>INFORMATION DISCLOSURE CITATION</b> MAY 22 2002 PATENT & TRADEMARK OFFICE		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. <b>AMI-011-RC2</b>	Serial No. <b>10/015,534</b>
(Use several sheets if necessary)				Applicant <b>Burton G. Christensen et al.</b>	
				Filing Date <b>December 13, 2001</b>	Group Art Unit <b>1627</b>
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)					
	C9	*Buckley et al., Mol. Pharmacol. 35:469-476 (1989)			
	C10	*Burnier et al., Exp. Opin. Invest. Drug 6(5):489-500 (1997)			
	C11	*Carini et al., J. Med. Chem. 34(8):2525-2547 (1991)			
	C12	*Carini et al., J. Med. Chem. 33(5):1330-1336 (1990)			
	C13	*Casas et al., J. Drugs Future 22(5):481-491 (1997)			
	C14	*Chiu et al., JPET 252(2):711-718 (1990)			
	C15	*Cvejic et al., J. Biol. Chem. 272(43):26959-26964 (1997)			
	C16	*Dixon et al., Nature 321:75-79 (1986)			
previously	C17	*Duncia et al., J. Med Chem. 33(5):1312-1329 (1990)			
	C18	*Dzielak, Exp. Opin. Invest. Drugs 7(5):741-751 (1998)			
considered	C19	*Eglen et al., DNP 10(8):462-469 (1997)			
	C20	*Eglen et al., Pharmacol. Toxicol. 78:59-68 (1996)			
	C21	*Ferro et al., Br. J. Clinical. Pharmacol. 40:245-251 (1995)			
	C22	*Fiorelli et al., J. Steroid. Biochem. Mol. Biol. 59(2):233-240 (1996)			
	C23	*Gardiner, Exp. Opin. Invest. Drug 7(3):405-411 (1998)			
	C24	*Garssen et al., Br. J. Pharmacol. 109:53-60 (1993)			
	C25	*George, J. Neurochem. 69(3):1278-1285 (1997)			
	C26	*Goadsby et al., Headaches 34:394-399 (1994)			
	C27	*Goadsby, "Animal models of migraine: which model, why and for what"? <i>Migraine and Headache Pathophysiology</i> , Chap. 14, Ed. L. Edvinsson, Martin Dunitz Ltd., London 1999			
	C28	*Green et al., J. Biol. Chem. 271(38):24029-24035 (1996)			
	C29	*Green et al., Mol. Pharmacol. 41:889-893 (1992)			
	C30	*Green et al., J. Biol. Chem. 269(42):26215-26219 (1994)			
	C31	*Hamel et al., Mol. Pharmacol. 44:242-246 (1993)			
	C32	*Heavner, DDT 1(7):295-304 (1996)			
	C33	*Hebert et al., J. Biol. Chem. 271(27):16384-16392 (1996)			
	C34	*Hebert et al., Biochem. Cell Biol. 76(1):1-11 (1998)			
	C35	*Holzgrabe et al., DDT 3(5):214-222 (1998)			
	C36	*Janssen, Drug Invest. 3(Suppl 1):1-2 (1991)			
	C37	*Kahne, Curr. Opin. Chem. Biol. 1(1):130-135 (1997)			
EXAMINER					
		DATE CONSIDERED <b>8/3/05</b>			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

<b>FORM PTO-1449</b> Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. <b>AMI-011-RC2</b>	Serial No. <b>10/105534</b>
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicant <b>Burton G. Christensen et al.</b>	
				Filing Date <b>December 13, 2001</b>	
				Group Art Unit <b>1627</b>	
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)					
	C38	*Kobilka et al., Nature 329:75-79 (1987)			
	C39	*Kretzschmar et al., Tet. Lett. 51(47):13015-13030 (1995)			
	C40	*Kukkonen et al., J. Pharmacol. Exp. Ther. 279(2):593-601 (1996)			
	C41	*Kukkonen et al., Biochem. Biophys. Res. Comm. 243(1):41-46 (1998)			
	C42	*Leboulluec et al., Bioorg. Med. Chem. Lett. 5(2):123-126 (1995)			
	C43	*Lee et al., Mol. Pharmacol. 50:140-148 (1996)			
	C44	*Liang et al., Science 274:1520-1522 (1996)			
	C45	*Liggett et al., Mol. Pharmacol. 36:641-646 (1989)			
	C46	*Lofdahl et al., Asthma 2:1523-1533 (1997)			
	C47	*Longmore et al., Br. J. Clin. Pharmacol. 42:431-441 (1996)			
	C48	*McClellan et al., Drugs 55(5):713-718 (1998)			
<i>Previously</i>	C49	*McCrea et al., Br. J. Pharmacol. 110:619-626 (1993)			
	C50	*MacLagan et al., TIPS (Suppl):88-92 (1989)			
<i>Considered</i>	C51	*Maggio et al., PNAS 90:3103-3107(1993)			
	C52	*Martel et al., Drugs Future 22(2):135-137 (1997)			
	C53	*Martin et al., Br. J. Pharmacol. 121:157-164 (1997)			
	C54	*Merlos et al., Drugs Future 22(8):850-855 (1997)			
	C55	*Monnot et al., J. Biol. Chem. 271(3):1507-1513 (1996)			
	C56	*Mukoyama et al., J. Biol. Chem. 268(33):24539-24542 (1993)			
	C57	*Nials et al., Br. J. Pharmacol. 110:1112-1116 (1993)			
	C58	*Nials et al., Eur. J. Pharmacol. 251:127-135 (1994)			
	C59	*Nikko/Masato et al., Chem Abstract 113(2):354 #11917g (1990)			
	C60	*Nimchinsky et al., J. Biol. Chem. 272(46):29229-29237 (1997)			
	C61	*Ngo et al., Drugs Future 22(3):260-269 (1997)			
	C62	*Pauwels et al., Biochem. Pharmacol. 45(2):375-383 (1993)			
	C63	*Pauwels et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 353:144-156 (1996)			
	C64	*Piergentili et al. II Farmaco 49(2):83-87 (1994)			
	C65	*Portoghese, J. Med. Chem. 35(11):1927-1937 (1992)			
	C66	*Riyero et al., Bioorg. Med. Chem. Lett. 3(4):557-560 (1993)			
	C67	*Ruffolo et al., J. Med Chem. 38(19):3681-3716 (1995)			
EXAMINER		DATE CONSIDERED			
		<b>6/3/05</b>			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

<b>FORM PTO-1449</b> Approved for use through 10/31/2002 <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. <b>AMI-011-RC2</b>	Serial No. <b>10/015,534</b>
				Applicant <b>Burton G. Christensen et al.</b>	
				Filing Date <b>December 13, 2001</b>	Group Art Unit <b>1627</b>
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)					
C68	*Schoeffter et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 340:135-138 (1989)				
C69	*Shuker et al., Science 274:1531-1534 (1996)				
C70	*Suh et al., Bioorg. Med. Chem. Lett. 7(4):389-392 (1997)				
C71	*Valentin et al., Br. J. Pharmacol. 119:35-42 (1996)				
C72	*Van de Water et al., Eur. J. Pharmacol. 299:127-137 (1996)				
C73	*Veldman et al., Mol. Pharmacol. 42:439-444 (1992)				
C74	*Waldeck et al., Eur. J. Pharmacol. 112(3):349-353 (1985)				
previously considered C75	*Waldeck et al., Acta Pharmacol. Toxicol. 58:209-218 (1986)				
C76	*Wexler et al., J. Med. Chem. 39(3):625-656 (1996)				
C77	*Wong et al., JPET 252(2):719-725 (1990)				
C78	*Wong et al., JPET 252(2):726-732 (1990)				
C79	*Wurch et al., Br. J. Pharmacol. 120:153-159 (1997)				
C80	*Yocca, Cephalgia 15(Suppl 14):174- (1995)				
C81	*Zakon, Trends Neurosci. 21:202-207 (1998)				
C82	*Zeng et al., J. Chrom. A 794:3-13 (1998)				
C83	*Zgombick et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 54:226-236 (1996)				
C84					
C85					
C86					
C87					
C88					
C89					
C90					
C91					
C92					
C93					
C94					
C95					
C96					
C97					
EXAMINER 				DATE CONSIDERED <b>6/3/05</b>	
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					